Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies-Reference-Cited by-同舟云学术

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

Published:2022-04-03 Issue:4 Volume:22 Page:383-400
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Motzer Robert J.¹,Taylor Matthew H.²,Evans Thomas R. Jeffry³⁴,Okusaka Takuji⁵,Glen Hilary⁴,Lubiniecki Gregory M.⁶,Dutcus Corina⁷,Smith Alan D.⁷,Okpara Chinyere E.⁷,Hussein Ziad⁸,Hayato Seiichi⁹,Tamai Toshiyuki¹⁰,Makker Vicky¹

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA

2. Division of Hematology and Oncology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA

3. Institute of Cancer Sciences, University of Glasgow, Glasgow, UK

4. Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK

5. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

6. Global Clinical Development, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

7. Clinical Research, Eisai Inc., Nutley, NJ, USA

8. Clinical Pharmacology Science, Eisai Europe Ltd, Hatfield, UK

9. Clinical Pharmacology Science, Eisai Co., Ltd, Tokyo, Japan

10. Clinical Research, Eisai Co., Ltd, Tokyo, Japan

Funder

Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. R.M. and V.M

Swati Khare, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2039123

Reference83 articles.

1. Lenvatinib

2. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

4. Eisai Co., Ltd., MSK K.K. Lenvima® (lenvatinib) approved for additional indication of unresectable thymic carcinoma in Japan [press release]. Mar 23. Available at: https://www.eisai.com/news/2021/news202120.html [Accessed December 17, 2021].

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world drug safety surveillance study of lenvatinib from the FAERS database;Expert Opinion on Drug Safety;2024-08-21

2. Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial;Frontiers in Oncology;2024-07-30

3. Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case;Frontiers in Oncology;2024-07-15

4. Disease-Modifying Effects of Lenvatinib, a Multiple Receptor Tyrosine Kinase Inhibitor, on Posttraumatic Osteoarthritis of the Knee;International Journal of Molecular Sciences;2024-06-13

5. Metastatic glioblastoma to the lungs: a case report and literature review;CNS Oncology;2024-06-06